Cargando…
Differing pan-coronavirus antiviral potency of boceprevir and GC376 in vitro despite discordant molecular docking predictions
Given the structural similarities of the viral enzymes of different coronaviruses (CoVs), we investigated the potency of the anti-SARS-CoV-2 agents boceprevir and GC376 for counteracting seasonal coronavirus infections. In contrast to previous findings that both boceprevir and GC376 are potent inhib...
Autores principales: | Wang, Yining, Li, Pengfei, Lavrijsen, Marla, Li, Yang, Ma, Zhongren, Peppelenbosch, Maikel P., Baig, Mirza S., Pan, Qiuwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853085/ https://www.ncbi.nlm.nih.gov/pubmed/35171357 http://dx.doi.org/10.1007/s00705-022-05369-y |
Ejemplares similares
-
Repurposing dyphylline as a pan-coronavirus antiviral therapy
por: Wang, Yining, et al.
Publicado: (2022) -
Nirmatrelvir exerts distinct antiviral potency against different human coronaviruses
por: Li, Jiajing, et al.
Publicado: (2023) -
Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease
por: Fu, Lifeng, et al.
Publicado: (2020) -
Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses
por: Wang, Yining, et al.
Publicado: (2021) -
Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture
por: Hu, Yanmei, et al.
Publicado: (2020)